Loading
A phase 3 trial of CAPOX, FLOT in colorectal cancer, run by Summit Therapeutics, now recruiting.
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07228832 by Summit Therapeutics, with 600 participants planned, started 2025-11-18 and due to reach its primary completion in 2028-05-31. Interventions recorded: Drug: Ivonescimab Injection, Drug: Bevacizumab Injection. Conditions listed: Metastatic Colorectal Cancer (CRC). No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.